Benfotiamine: The Fat-Soluble B1 That Actually Gets Absorbed
Last updated: March 2026
Benfotiamine (S-benzoylthiamine O-monophosphate) is a synthetic fat-soluble derivative of thiamine with dramatically higher bioavailability than standard vitamin B1. Clinical trials demonstrate benefits for diabetic neuropathy, AGE (advanced glycation end-product) reduction, and early-stage Alzheimer's cognitive decline.
vs. Thiamine HCl
Studies on PubMed
Dose Range
What Is Benfotiamine?
Benfotiamine is a synthetic S-acyl derivative of thiamine (vitamin B1). Unlike water-soluble thiamine HCl, benfotiamine is lipid-soluble — it passively diffuses across intestinal membranes rather than relying on saturable active transport, resulting in dramatically higher blood and tissue thiamine levels.
Benfotiamine activates transketolase, which shunts excess glucose metabolites into the pentose phosphate pathway — away from AGE (advanced glycation end-product) formation. AGEs are toxic protein modifications linked to diabetic complications, neurodegeneration, and aging. In the Alzheimer's trial (Gibson et al. 2020, PMID: 33074237), benfotiamine significantly reduced blood AGE levels (p = 0.044).
Transketolase is the thiamine diphosphate (ThDP)-dependent enzyme at the heart of the pentose phosphate pathway. Benfotiamine raises intracellular ThDP levels far more effectively than regular thiamine, supercharging this enzyme. Hammes et al. (2003, PMID: 12592403) showed benfotiamine blocked three major pathways of hyperglycemic damage in diabetic animal models via this mechanism.
In transgenic Alzheimer's mouse models, benfotiamine reduced amyloid-β plaques, decreased phosphorylated tau, and improved cognitive performance (Pan et al. 2010, PMID: 20385653). Tapias et al. (2018, PMID: 29860433) showed benfotiamine activated the Nrf2/ARE antioxidant pathway and was neuroprotective in a tauopathy model. The human Phase IIa trial showed 77% less clinical worsening on the CDR scale (p = 0.034).
Benfotiamine modulates NF-κB signaling, arachidonic acid inflammation pathways, and protein kinase B cascades. It prevents macrophage death from lipopolysaccharide challenge and inhibits monocyte adhesion to endothelial cells. In activated microglia, it inhibits inflammatory mediators and enhances anti-inflammatory factor production — relevant to both diabetic complications and neurodegeneration.
Bioavailability: Why Form Matters
Water-soluble thiamine (B1) has a hard absorption ceiling — the intestinal transporter saturates at relatively low doses. Fat-soluble derivatives bypass this bottleneck entirely.
Key study: Xie et al. (2014, PMID: 24399744) measured plasma thiamine bioavailability of benfotiamine at 1,147% ± 490% relative to thiamine HCl — roughly an 11× improvement. Erythrocyte TDP (the active coenzyme form) was 196% of thiamine HCl. Earlier work by Bitsch et al. (1991, PMID: 1776825) reported approximately 5× greater bioavailability in a 10-subject crossover study.
Important nuance: Benfotiamine is the champion for raising blood and peripheral tissue thiamine levels. However, unlike sulbutiamine and TTFD, benfotiamine may not cross the blood-brain barrier as effectively. Its central effects in the Alzheimer's trial may work through peripheral AGE reduction and anti-inflammatory mechanisms rather than direct CNS thiamine delivery.
What the Clinical Trials Show
Data from published human clinical trials on benfotiamine across neuropathy, diabetes, and neurodegeneration.
Note on evidence quality: Benfotiamine has real human trial data — including a 12-month randomized placebo-controlled Alzheimer's trial and the BENDIP neuropathy RCT. Most trials are small-to-moderate in size. The evidence is promising but requires larger confirmatory studies.
Alzheimer's & Neurodegeneration
Benfotiamine is one of the few supplements with an actual randomized placebo-controlled trial specifically for Alzheimer's disease. Here are the key studies.
600mg/day benfotiamine in MCI/mild AD patients. CDR worsening reduced 77% (p = 0.034), ADAS-Cog decline reduced 43% (p = 0.125, not significant), AGE reduced (p = 0.044), FDG-PET improved (p = 0.002). Safe and well-tolerated over 12 months. Phase IIb trial (BenfoTeam) is planned.
In Alzheimer's transgenic mice (APP/PS1), benfotiamine reduced amyloid-β plaque numbers, decreased phosphorylated tau levels, elevated phosphorylation of GSK-3α/β, and improved memory performance. Provided the preclinical basis for the human trial.
In a transgenic tauopathy model, benfotiamine activated the Nrf2/ARE antioxidant defense pathway, reduced tangle formation, and improved behavioral deficits. Demonstrates a direct neuroprotective mechanism beyond simple AGE reduction.
165 patients with diabetic polyneuropathy randomized to benfotiamine 300mg/day, 600mg/day, or placebo. NSS (Neuropathy Symptom Score) significantly improved at 600mg in per-protocol population (p = 0.033). Improvement was dose-dependent and increased with treatment duration. TSS (Total Symptom Score) showed no significant difference at 6 weeks.
Does Benfotiamine Raise IQ? The Viral Nootropic Claims, Examined
The straight answer: no human study has ever measured benfotiamine raising IQ or improving cognition in healthy people. Every human cognition dataset comes from Alzheimer's or MCI patients — not students, biohackers, or anyone chasing a nootropic edge.
Bottom line up front: The viral threads promising a "significant IQ boost," "perfect memory," or surges in dopamine, motivation, and metacognition are extrapolating from sick-brain trials and animal data — there is zero human enhancement data behind them.
The only two human cognition datasets both come from dementia populations. In the Phase IIa RCT (Gibson et al. 2020, PMID 33074237), 600 mg/day for 12 months was given to MCI and mild-AD patients — and its primary cognitive endpoint (ADAS-Cog) missed statistical significance (p = 0.125). The encouraging numbers — 77% less CDR worsening (p = 0.034), lower blood AGEs (p = 0.044), better FDG-PET (p = 0.002) — were all secondary. That is an early, unconfirmed signal in already-impaired brains — not proof of enhancement in healthy ones. The second dataset, Pan et al. 2016 (PMID 27696179), is a tiny open-label Alzheimer's pilot — no placebo, no blinding, a disease population. It only underscores the point: every scrap of human cognition data is in AD patients.
The one human source those threads usually cite — "the study on epileptics" — does not exist. A PubMed search for benfotiamine and epilepsy returns nothing.
The "crosses the blood-brain barrier better than anything and stays in the brain" claim is wrong in both directions. Benfotiamine is an S-acyl thiamine precursor that is largely dephosphorylated and converted to thiamine in the gut and periphery; whether meaningful amounts reach the human brain is debated, not established. But it isn't zero either — in a rat neurodegeneration model, brain thiamine-diphosphate did rise (Moraes et al. 2020, PMID 32987117), so "zero brain penetration" is also false. A rat disease model is still not a healthy human IQ. The thiamine derivatives actually engineered to cross the BBB are sulbutiamine and TTFD.
Finally, "no toxicity, take a couple grams a day" overshoots every trial. The studied safety ceiling is 600 mg/day for 12 months (Gibson 2020); multi-gram dosing is beyond any human data. If you are specifically chasing cognitive or CNS effects, benfotiamine is the wrong tool. What benfotiamine is genuinely good for is covered above on this page: AGE/glycation reduction and diabetic-neuropathy symptom relief.
Chasing cognition instead? Start with the Cognitive research hub and the two BBB-penetrant B1 forms — sulbutiamine and TTFD — which are built for the central effects benfotiamine was never designed to deliver.
Dosing Guide
Benfotiamine dosing from published clinical trials and common supplementation protocols. Always start low and assess tolerance.
- Daily maintenance dose
- General B1 optimization
- AGE prevention support
- Take with a fat-containing meal for best absorption
- BENDIP trial used 300mg and 600mg/day
- 600mg showed significant NSS improvement
- Split into 2 doses (morning + evening)
- Minimum 6 weeks for assessment
- AD trial used 600mg/day (300mg BID)
- Some protocols go up to 900mg
- Requires medical supervision
- 12-month trial showed safe at 600mg
Benfotiamine works within the B-vitamin metabolic network. These cofactors support its mechanisms and prevent downstream bottlenecks:
Safety & Side Effects
Benfotiamine has an excellent safety record across clinical trials. As a B-vitamin derivative, excess is generally excreted rather than accumulated.
Key Takeaways
An honest assessment of the benfotiamine research as of 2026.
- 5-11× higher plasma thiamine levels than standard B1 (Xie et al. 2014, Bitsch et al. 1991)
- Significantly reduces AGE levels in Alzheimer's patients (p = 0.044)
- 77% less CDR worsening vs placebo over 12 months (p = 0.034)
- Improves neuropathy symptoms at 600mg/day in BENDIP trial (p = 0.033)
- Blocks three of four major hyperglycemic damage pathways via transketolase
- Safe and well-tolerated at 600mg/day for 12 months in an AD population
- Strong preclinical evidence: reduces amyloid-β, tau, activates Nrf2/ARE pathway
- Primary ADAS-Cog endpoint didn't reach significance in Phase IIa (p = 0.125)
- Whether benfotiamine crosses the blood-brain barrier effectively (debated)
- Optimal dose for neuroprotection vs peripheral AGE reduction
- Long-term outcomes beyond 12 months
- Whether benefits are limited to APOE ε4 non-carriers (subgroup effect)
- How it compares to TTFD or sulbutiamine for CNS effects
- Phase IIb confirmatory trial (BenfoTeam) is planned but not yet completed
🛒 Recommended Products
Benfotiamine supplements and companion products for B1 optimization.
Affiliate links — support HighPeptides at no extra cost.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide — $19 (normally $29) →
New to peptides? Start with the $19 Buyer’s Playbook →
This page is for educational and informational purposes only. It is not medical advice. Benfotiamine is sold as a dietary supplement in the United States. It is not an FDA-approved drug for any condition. The clinical trials cited on this page are preliminary and do not constitute proof of efficacy for treating, curing, or preventing any disease. Always consult a qualified healthcare provider before starting any supplement regimen, especially if you have diabetes, neuropathy, or cognitive concerns. Individual responses vary significantly. HighPeptides does not provide medical advice or sell supplements.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.